Skip to main
PAYS

PaySign Inc (PAYS) Stock Forecast & Price Target

PaySign Inc (PAYS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PaySign is supported by rapid momentum in its Pharmaceutical Patient Affordability business, where 2Q revenue jumped 89% Y/Y to $14.6M and active programs rose to 148, with 17 net new campaigns added in the first half of 2026 and another 9 in July. Its profitability is also inflecting sharply as mix shifts toward higher-margin Pharma offerings, driving 2Q adjusted EBITDA up 113% Y/Y to $9.6M and margin expansion to 34.0%, while management raised 2026 guidance to 39%-43% revenue growth and $35.0M-$38.0M adjusted EBITDA. A strong balance sheet, including $27.4M of unrestricted cash, $149.1M of restricted cash, no debt, and $6.8M of 2Q adjusted free cash flow, gives it flexibility for acquisitions and repurchases while the Plasma segment and Apherion add further growth optionality.

Bears say

PaySign is a highly niche-dependent payments provider whose fundamentals remain vulnerable because the domestic Plasma Donor Compensation business generated just over 55% of revenue in 2025, while center counts fell sequentially and to 561 in 2Q26 after a customer closed locations. Although revenue in that segment grew 21% Y/Y to $13.0M in 2Q26, the company has already shown how quickly demand shocks can pressure results, as 2020 revenue dropped 30% Y/Y to $24M and adjusted EBITDA swung to a $2.8M loss from $10.1M in 2019. Its outlook is further restrained by intense competition, regulatory and bank-partner dependence, and the loss of legacy Pharma Prepaid contracts in late 2022, which weakens diversification and lowers the quality of recurring revenue.

PaySign Inc (PAYS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PaySign Inc (PAYS) Forecast

Analysts have given PaySign Inc (PAYS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, PaySign Inc (PAYS) has a Strong Buy consensus rating as of Oct 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PaySign Inc (PAYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.